Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face

NCT ID: NCT00986570

Last Updated: 2015-12-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 121 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2010-11-30

Brief Summary

The purpose of this study is to determinate whether Xeomin® (Botulinum toxin Type A) is safe, effective and tolerable in woman aged 30 to 50 years old for treatment of mild, moderate or severe expression lines (wrinkles) in the upper third of the face. The main outcome was the change in appearance of the wrinkles two weeks (visit 3) after product application as compared with baseline assessment.

Detailed Description

Ageing is a dynamic and unchangeable process involving all individuals and affecting the several organic systems. This process is expressed through multiple symptoms and signs, the wrinkles and flaccidity being the most common and visible ones.

In both developed and emerging countries, the interest in skin ageing is, to a greater extent, the result of the progressive increase in the absolute number and the proportion of people experiencing the ageing process in the last century. The psychosocial, as well as the physiological effects of the skin ageing raised a huge demand for a better understanding of this process and, in particular, of the effective interventions.

The use of the botulinum toxin type-A (BTX/A) for aesthetic indication emerged as a result of the clinical observation of those patients treated for facial different dystonia and who presented additional improvement of their expression lines.

The expression lines are most easily noted on the upper third of the face, where surgical treatments are fully invasive and show lesser noticeable results. The upper third of the face was targeted for BTX/A treatment and reported in several scientific literature articles as well succeeded.

Conditions

Skin Aging

Keywords

Botulinum Toxin A; Wrinkles

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Xeomin®

Botulinum Toxin A

Group Type: EXPERIMENTAL

Botulinum Toxin A

Intervention Type: BIOLOGICAL

100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.

Interventions

Botulinum Toxin A

100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.

Intervention Type: BIOLOGICAL

Other Intervention Names

Xeomin®

Eligibility Criteria

Inclusion Criteria

• Women aged 30 to 50 years old, inclusive.
• Mild, moderate or severe expression wrinkles.
• Patients who had understood and signed the Informed Consent Form.

Exclusion Criteria

• Subjects treated with botulinum toxin on the upper third of the face within the previous 6-month period;
• Former implantation of permanent material and surgery (scars).
• Use of any anticoagulant agent up to 7 days prior to the investigational product application;
• Concomitant use of aminoglycosides or of any other drug that may impair in the neuromuscular transmission;
• Coagulopathies and local inflammation/ infection at the application site.
• Diseases which do impact on the neuromuscular function, such as: myasthenia gravis, Eaton Lambert Syndrome;
• Pregnancy or breast feeding, women with potential to become pregnant or who do not agree to use an effective contraception method (Pearl Index < 1%);
• Allergy or known sensitivity to any of the components of the investigational drug;
• Subjects who were enrolled in other clinical trial for the last 12-month period prior to the present study, as per Resolution 251/97;
• Subjects who disagree with the study procedures, who do not sign the Informed Consent Form or who are not committed to participate in the trial.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Biolab Sanus Farmaceutica

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sergio Talarico, MD

Role: PRINCIPAL_INVESTIGATOR

Federal University of São Paulo

Locations

Universidade Federal de São Paulo/Hospital São Paulo

São Paulo, São Paulo, Brazil

Countries

Brazil

Other Identifiers

XEO-001/07

Identifier Type: -

Identifier Source: org_study_id